IP Library Granted Patent US 12,357,732
Granted Patent B2
US 12,357,732 · App. 18/219,837 · Granted Jul 15, 2025

Drug coated balloon catheters for nonvascular strictures

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN)
Assignee: Urotronic, Inc.
A61L29/16A61K31/337A61K31/439A61L29/08A61P31/00A61P37/06A61L2300/416A61M25/10A61M2025/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,732
App. No.
18/219,837
Granted
Jul 15, 2025
Kind
B2
Abstract

Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Claims (29)

1. A method of treating a nonvascular body lumen, the method comprising:

contacting a coating on a medical device in a body lumen with walls of the body lumen, wherein the coating comprises a liquid comprising water, the body lumen comprising a nasal lumen, a sinus lumen, an airway lumen, a bronchial lumen, a bronchiole lumen, a trachea, or a combination thereof, the coating comprising at least one additive and an initial drug load of a therapeutic agent comprising paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, or a combination thereof.

2. The method of claim 1 , wherein the medical device comprises a balloon catheter.

3. The method of claim 1 , wherein the medical device comprises a stent.

4. The method of claim 1 , wherein:

the method is effective to inhibit hyperplasia of the walls of the body lumen that are contacted with the coating; or

the method is effective to relieve symptoms of sinusitis, asthma, or a combination thereof; or

a combination thereof.

5. The method of claim 1 , wherein the body lumen comprises a nasal lumen, a sinus lumen, or a combination thereof, and the method is effective to relieve symptoms of sinusitis.

6. The method of claim 1 , wherein the body lumen comprises an airway lumen, a bronchial lumen, a bronchiole lumen, a trachea, or a combination thereof, and the method is effective to relieve symptoms of asthma.

7. The method of claim 1 , wherein the additive comprises pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate/ethoxylate, or a combination thereof.

8. The method of claim 1 , wherein the additive comprises pentaerythritol ethoxylate ¾ EO/OH, pentaerythritol ethoxylate 15/4 EO/OH, or a combination thereof.

9. The method of claim 1 , wherein the additive comprises pentaerythritol ethoxylate 15/4 EO/OH.

10. The method of claim 1 , further comprising flushing the body lumen with the liquid comprising water prior to the contacting of the coating with the walls of the body lumen, or soaking the coating in the liquid comprising water prior to the contacting of the coating with the walls of the body lumen, to introduce the liquid comprising water into the coating.

11. The method of claim 10 , comprising performing the soaking of the coating outside the body.

12. The method of claim 10 , comprising performing the soaking of the coating in the body lumen.

13. The method of claim 10 , wherein the flushing or soaking in combination with the contacting of the coating with the walls of the body lumen is sufficient to release 37% to 97% of the initial drug load.

14. The method of claim 10 , wherein the coating is soaked for a time of at least 1 minute.

15. The method of claim 1 , further comprising prior the contacting of the coating with the walls of the body lumen:

inserting an uncoated balloon catheter into the body lumen;

inflating the uncoated balloon catheter until the balloon contacts the walls of the body lumen;

deflating the uncoated balloon; and

withdrawing the uncoated balloon from the body lumen.

16. The method of claim 1 , wherein a ratio by weight of the therapeutic agent to the total weight of the additive in the coating is from 2 to 6, and wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the medical device.

17. The method of claim 1 , wherein the contacting of the coating on the medical device in the body lumen with walls of the body lumen comprises dilating the body lumen to a desired size.

18. A method of treating a nonvascular body lumen, the method comprising:

contacting a coating on a medical device in a body lumen with walls of the body lumen, wherein the coating comprises a liquid comprising water, the body lumen comprising a nasal lumen, a sinus lumen, or a combination thereof, the coating comprising at least one additive comprising pentaerythritol ethoxylate 15 / 4 EO/OH and an initial drug load of a therapeutic agent comprising paclitaxel, a paclitaxel analogue, or a combination thereof.

19. A method of treating a nonvascular body lumen, the method comprising:

contacting a coating on a medical device in a body lumen with walls of the body lumen, wherein the coating comprises a liquid comprising water, the body lumen comprising an airway lumen, a bronchial lumen, a bronchiole lumen, a trachea, or a combination thereof, the coating comprising at least one additive comprising pentaerythritol ethoxylate 15/4 EO/OH and an initial drug load of a therapeutic agent comprising paclitaxel, a paclitaxel analogue, or a combination thereof.

Assignments (4)
SECURITY INTEREST Recorded Jul 23, 2024
From: NOVONATE INC.; PELVALON, INC.; UROTRONIC, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 068057/0959 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: UROTRONIC, INC.
Reel/Frame 066989/0836 →
SECURITY INTEREST Recorded Dec 12, 2023
From: UROTRONIC, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 065839/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2023
From: WANG, LIXIAO; BARNETT, PETER
To: UROTRONIC, INC.
Reel/Frame 064197/0631 →
Continuity (7)
Continuation 18214131 · Jun 26, 2023
Continuation 18097690 · Jan 17, 2023
Continuation 17951321 · Sep 23, 2022
Continuation 17107136 · Nov 30, 2020
Continuation 15568614
Provisional Application 62152559 · Apr 24, 2015
Related Publication 20230372593A1 · Nov 23, 2023
References Cited (400)
US 1686437A · Thomas et al. · 1928 [cited by applicant]
US 5171299A · Heitzmann et al. · 1992 [cited by applicant]
US 5263931A · Miller · 1993 [cited by applicant]
US 5312430A · Rosenbluth et al. · 1994 [cited by applicant]
US 5314443A · Rudnick · 1994 [cited by applicant]
US 5419763A · Hildebrand · 1995 [cited by applicant]
US 5423755A · Kesten et al. · 1995 [cited by applicant]
US 5562620A · Klein et al. · 1996 [cited by applicant]
US 5718684A · Gupta · 1998 [cited by applicant]
US 5752522A · Murphy · 1998 [cited by applicant]
US 5904648A · Arndt et al. · 1999 [cited by applicant]
US 6059713A · Urick et al. · 2000 [cited by applicant]
US 6268390B1 · Kunz · 2001 [cited by applicant]
US 6306421B1 · Kunz et al. · 2001 [cited by applicant]
US 6403635B1 · Kinsella et al. · 2002 [cited by applicant]
US 6488653B1 · Lombardo · 2002 [cited by applicant]
US 6495579B1 · Hunter · 2002 [cited by applicant]
US 6515009B1 · Kunz et al. · 2003 [cited by applicant]
US 6530948B1 · Vrba · 2003 [cited by applicant]
US 6579221B1 · Peterson · 2003 [cited by applicant]
US 6663881B2 · Kunz et al. · 2003 [cited by applicant]
US 6730064B2 · Ragheb et al. · 2004 [cited by applicant]
US 7803149B2 · Bates et al. · 2010 [cited by applicant]
US 7811622B2 · Bates et al. · 2010 [cited by applicant]
US 7882841B2 · Aljuri · 2011 [cited by examiner]
US 8052668B2 · Sih · 2011 [cited by applicant]
US 8092864B2 · Isch et al. · 2012 [cited by applicant]
US 8241249B2 · Wang · 2012 [cited by applicant]
US 8244344B2 · Wang · 2012 [cited by applicant]
US 8257305B2 · Speck et al. · 2012 [cited by applicant]
US 8366660B2 · Wang · 2013 [cited by applicant]
US 8366662B2 · Wang · 2013 [cited by applicant]
US 8403910B2 · Wang · 2013 [cited by applicant]
US 8404300B2 · Wang · 2013 [cited by applicant]
US 8414525B2 · Wang · 2013 [cited by applicant]
US 8414526B2 · Wang · 2013 [cited by applicant]
US 8414909B2 · Wang · 2013 [cited by applicant]
US 8414910B2 · Wang · 2013 [cited by applicant]
US 8425459B2 · Wang · 2013 [cited by applicant]
US 8430055B2 · Wang et al. · 2013 [cited by applicant]
US 8439868B2 · Speck et al. · 2013 [cited by applicant]
US 8557272B2 · Zhao · 2013 [cited by applicant]
US 8586125B2 · Hossainy et al. · 2013 [cited by applicant]
US 8673387B2 · Bates et al. · 2014 [cited by applicant]
US 8722132B2 · Labrecque et al. · 2014 [cited by applicant]
US 9066990B2 · Speck et al. · 2015 [cited by applicant]
US 9242081B2 · Drasler et al. · 2016 [cited by applicant]
US 9728840B2 · Shi et al. · 2017 [cited by applicant]
US 10245419B2 · Drasler et al. · 2019 [cited by applicant]
US 10668188B2 · Wang · 2020 [cited by applicant]
US 10675386B2 · Wang · 2020 [cited by applicant]
US 10806830B2 · Wang et al. · 2020 [cited by applicant]
US 10850076B2 · Wang et al. · 2020 [cited by applicant]
US 10881839B2 · Wang et al. · 2021 [cited by applicant]
US 10888640B2 · Wang · 2021 [cited by examiner]
US 10898700B2 · Wang et al. · 2021 [cited by applicant]
US 10987451B2 · Wang et al. · 2021 [cited by applicant]
US 10994103B2 · Wang et al. · 2021 [cited by applicant]
US 10994104B2 · Wang · 2021 [cited by examiner]
US 11439801B2 · Wang et al. · 2022 [cited by applicant]
US 11471655B2 · Wang et al. · 2022 [cited by applicant]
US 11471656B2 · Wang et al. · 2022 [cited by applicant]
US 11484628B2 · Wang · 2022 [cited by examiner]
US 11504450B2 · Wang et al. · 2022 [cited by applicant]
US 11648337B2 · Wang et al. · 2023 [cited by applicant]
US 11648338B2 · Wang et al. · 2023 [cited by applicant]
US 11730864B2 · Wang et al. · 2023 [cited by applicant]
US 11826532B2 · Wang et al. · 2023 [cited by applicant]
US 11826533B2 · Wang et al. · 2023 [cited by applicant]
US 11904072B2 · Wang et al. · 2024 [cited by applicant]
US 11925729B2 · Wang et al. · 2024 [cited by applicant]
US 11938287B2 · Wang et al. · 2024 [cited by applicant]
US 11957853B2 · Wang et al. · 2024 [cited by applicant]
US 12005206B2 · Wang et al. · 2024 [cited by applicant]
US 12102737B2 · Wang et al. · 2024 [cited by applicant]
US 12115286B2 · Wang et al. · 2024 [cited by applicant]
US 20030203991A1 · Schottman et al. · 2003 [cited by applicant]
US 20040098019A1 · Tomaschko et al. · 2004 [cited by applicant]
US 20040144387A1 · Amar · 2004 [cited by applicant]
US 20040267355A1 · Scott et al. · 2004 [cited by applicant]
US 20050054978A1 · Segal et al. · 2005 [cited by applicant]
US 20050196518A1 · Stenzel · 2005 [cited by applicant]
US 20050249770A1 · Hunter · 2005 [cited by applicant]
US 20060083768A1 · Labrecque et al. · 2006 [cited by applicant]
US 20070005094A1 · Eaton et al. · 2007 [cited by applicant]
US 20070009692A1 · Wang et al. · 2007 [cited by applicant]
US 20070027523A1 · Toner et al. · 2007 [cited by applicant]
US 20070031371A1 · Kozlowski · 2007 [cited by applicant]
US 20070088255A1 · Toner et al. · 2007 [cited by applicant]
US 20070260178A1 · Skerven et al. · 2007 [cited by applicant]
US 20080025952A1 · Scheule et al. · 2008 [cited by applicant]
US 20080113035A1 · Hunter · 2008 [cited by applicant]
US 20080118544A1 · Wang · 2008 [cited by applicant]
US 20080175887A1 · Wang · 2008 [cited by examiner]
US 20080245375A1 · Trudel · 2008 [cited by applicant]
US 20080255508A1 · Wang · 2008 [cited by applicant]
US 20080255509A1 · Wang · 2008 [cited by applicant]
US 20080255510A1 · Wang · 2008 [cited by applicant]
US 20080276935A1 · Wang · 2008 [cited by applicant]
US 20090018565A1 · To et al. · 2009 [cited by applicant]
US 20090028920A1 · Hodges · 2009 [cited by applicant]
US 20090171241A1 · Garcia et al. · 2009 [cited by applicant]
US 20090283206A1 · Eskaros et al. · 2009 [cited by applicant]
US 20100015200A1 · McClain et al. · 2010 [cited by applicant]
US 20100030183A1 · Toner et al. · 2010 [cited by applicant]
US 20100049182A1 · Ryan et al. · 2010 [cited by applicant]
US 20100055294A1 · Wang et al. · 2010 [cited by applicant]
US 20100076402A1 · Mazzone et al. · 2010 [cited by applicant]
US 20100198150A1 · Michal et al. · 2010 [cited by applicant]
US 20100209472A1 · Wang · 2010 [cited by applicant]
US 20100233228A1 · Speck · 2010 [cited by applicant]
US 20100285085A1 · Stankus et al. · 2010 [cited by applicant]
US 20110008260A1 · Flanagan · 2011 [cited by applicant]
US 20110015664A1 · Kangas et al. · 2011 [cited by applicant]
US 20110098683A1 · Wiita et al. · 2011 [cited by applicant]
US 20110144578A1 · Pacetti et al. · 2011 [cited by applicant]
US 20110159169A1 · Wang · 2011 [cited by applicant]
US 20110160575A1 · Beyar et al. · 2011 [cited by applicant]
US 20110160658A1 · Wang · 2011 [cited by applicant]
US 20110160660A1 · Wang · 2011 [cited by applicant]
US 20110166548A1 · Wang · 2011 [cited by applicant]
US 20110196340A1 · Barry et al. · 2011 [cited by applicant]
US 20110295200A1 · Speck et al. · 2011 [cited by applicant]
US 20110300221A1 · Kunz et al. · 2011 [cited by applicant]
US 20120029426A1 · Wang · 2012 [cited by applicant]
US 20120035530A1 · Wang · 2012 [cited by applicant]
US 20120109105A1 · Cambronne · 2012 [cited by applicant]
US 20120130174A1 · Simmons · 2012 [cited by applicant]
US 20120172796A1 · Chappa · 2012 [cited by applicant]
US 20120231037A1 · Levi et al. · 2012 [cited by applicant]
US 20120239001A1 · Barry et al. · 2012 [cited by applicant]
US 20120296274A1 · Slager · 2012 [cited by examiner]
US 20120302954A1 · Zhao · 2012 [cited by applicant]
US 20120316633A1 · Flanagan et al. · 2012 [cited by applicant]
US 20130197434A1 · Wang · 2013 [cited by applicant]
US 20130197436A1 · Wang · 2013 [cited by applicant]
US 20130231638A1 · Speck et al. · 2013 [cited by applicant]
US 20130245058A1 · Hoffmann et al. · 2013 [cited by applicant]
US 20130253466A1 · Campbell et al. · 2013 [cited by applicant]
US 20130253475A1 · Wang · 2013 [cited by applicant]
US 20130261603A1 · Wang · 2013 [cited by applicant]
US 20130304029A1 · Barry et al. · 2013 [cited by applicant]
US 20140005541A1 · Bates et al. · 2014 [cited by applicant]
US 20140031843A1 · Rottenberg et al. · 2014 [cited by applicant]
US 20140228751A1 · Speck et al. · 2014 [cited by applicant]
US 20140228752A1 · Speck et al. · 2014 [cited by applicant]
US 20140378896A1 · Venturelli · 2014 [cited by applicant]
US 20150231375A1 · Kubo et al. · 2015 [cited by applicant]
US 20150273117A1 · Wang · 2015 [cited by applicant]
US 20160038648A1 · Gemborys · 2016 [cited by applicant]
US 20160082159A1 · Orlowski · 2016 [cited by applicant]
US 20160250388A1 · Wang · 2016 [cited by applicant]
US 20160338793A1 · Shohat et al. · 2016 [cited by applicant]
US 20170028105A1 · Ahlering et al. · 2017 [cited by applicant]
US 20170086929A1 · Moll et al. · 2017 [cited by applicant]
US 20170274179A1 · Sullivan et al. · 2017 [cited by applicant]
US 20180104383A1 · Wang et al. · 2018 [cited by applicant]
US 20190015639A1 · Wang et al. · 2019 [cited by applicant]
US 20190015640A1 · Wang et al. · 2019 [cited by applicant]
US 20190167854A1 · Wang · 2019 [cited by applicant]
US 20190344053A1 · Wang et al. · 2019 [cited by applicant]
US 20190374685A1 · Wang et al. · 2019 [cited by applicant]
US 20200254148A1 · Wang · 2020 [cited by applicant]
US 20200360571A1 · Wang et al. · 2020 [cited by applicant]
US 20210052862A1 · Wang et al. · 2021 [cited by applicant]
US 20210052863A1 · Wang et al. · 2021 [cited by applicant]
US 20210052864A1 · Wang et al. · 2021 [cited by applicant]
US 20210052865A1 · Wang et al. · 2021 [cited by applicant]
US 20210077666A1 · Wang et al. · 2021 [cited by applicant]
US 20210113742A1 · Wang et al. · 2021 [cited by applicant]
US 20210113823A1 · Wang et al. · 2021 [cited by applicant]
US 20210205502A1 · Wang et al. · 2021 [cited by applicant]
US 20210228780A1 · Wang et al. · 2021 [cited by applicant]
US 20210361918A1 · Wang et al. · 2021 [cited by applicant]
US 20220323653A1 · Wang et al. · 2022 [cited by applicant]
US 20220323732A1 · Wang et al. · 2022 [cited by applicant]
US 20230001163A1 · Wang et al. · 2023 [cited by applicant]
US 20230020891A1 · Wang et al. · 2023 [cited by applicant]
US 20230050453A1 · Wang et al. · 2023 [cited by applicant]
US 20230149602A1 · Wang et al. · 2023 [cited by applicant]
US 20230149672A1 · Wang et al. · 2023 [cited by applicant]
US 20230173240A1 · Wang et al. · 2023 [cited by applicant]
US 20230347022A1 · Wang et al. · 2023 [cited by applicant]
US 20240042183A1 · Wang et al. · 2024 [cited by applicant]
US 20240042184A1 · Wang et al. · 2024 [cited by applicant]
US 20240165303A1 · Wang et al. · 2024 [cited by applicant]
US 20240173525A1 · Wang et al. · 2024 [cited by applicant]
US 20240269439A1 · Wang et al. · 2024 [cited by applicant]
CN 101273926A · 2008 [cited by applicant]
CN 101610798A · 2009 [cited by applicant]
CN 101631514A · 2010 [cited by applicant]
CN 102357278A · 2012 [cited by applicant]
CN 202191333U · 2012 [cited by applicant]
CN 102573946A · 2012 [cited by applicant]
CN 203138758U · 2013 [cited by applicant]
CN 103328033 · 2013 [cited by applicant]
CN 103458954 · 2013 [cited by applicant]
CN 104780859 · 2015 [cited by applicant]
CN 104936629A · 2015 [cited by applicant]
CN 107088258 · 2017 [cited by applicant]
CN 107635593A · 2018 [cited by applicant]
CN 109414528A · 2019 [cited by applicant]
CN 111166942A · 2020 [cited by applicant]
CN 113727750A · 2021 [cited by applicant]
CN 109414528B · 2022 [cited by applicant]
CN 115227880A · 2022 [cited by applicant]
CN 118236560A · 2024 [cited by applicant]
CN 118320191A · 2024 [cited by applicant]
CN 118454075A · 2024 [cited by applicant]
CN 113727750B · 2024 [cited by applicant]
EP 0474906A1 · 1992 [cited by applicant]
EP 1135165A1 · 2001 [cited by applicant]
EP 1143968B1 · 2003 [cited by applicant]
EP 1384840A1 · 2004 [cited by applicant]
EP 1539266B1 · 2008 [cited by applicant]
EP 2292225B1 · 2012 [cited by applicant]
EP 2098230B1 · 2012 [cited by applicant]
EP 2262547B1 · 2013 [cited by applicant]
EP 2324866B1 · 2014 [cited by applicant]
EP 2324867B1 · 2014 [cited by applicant]
EP 2531229B1 · 2014 [cited by applicant]
EP 2451496B1 · 2015 [cited by applicant]
EP 2911711 · 2015 [cited by applicant]
EP 3442612B1 · 2020 [cited by applicant]
JP H06343597A · 1994 [cited by applicant]
JP 2001238953 · 2001 [cited by applicant]
JP 2007229499 · 2007 [cited by applicant]
JP 2008541835 · 2008 [cited by applicant]
JP 2009022759 · 2009 [cited by applicant]
JP 2010540159A · 2010 [cited by applicant]
JP 2011024953 · 2011 [cited by applicant]
JP 2012502690A · 2012 [cited by applicant]
JP 2013001415 · 2013 [cited by applicant]
JP 2013523209A · 2013 [cited by applicant]
JP 2014523790A · 2014 [cited by applicant]
JP 2015536709A · 2015 [cited by applicant]
JP 2016503330A · 2016 [cited by applicant]
JP 2016036730A · 2016 [cited by applicant]
JP 2016518200A · 2016 [cited by applicant]
JP 2017507741A · 2017 [cited by applicant]
JP 2018517454A · 2018 [cited by applicant]
JP 2019137680A · 2019 [cited by applicant]
JP 2019523032A · 2019 [cited by applicant]
JP 2019218354A · 2019 [cited by applicant]
JP 2020049269A · 2020 [cited by applicant]
JP 2020075155A · 2020 [cited by applicant]
JP 6833218B2 · 2021 [cited by applicant]
JP 2021072908A · 2021 [cited by applicant]
JP 2022521000A · 2022 [cited by applicant]
JP 2023052847A · 2023 [cited by applicant]
JP 2023082069A · 2023 [cited by applicant]
JP 2024110887A · 2024 [cited by applicant]
WO WO9728840A1 · 1997 [cited by applicant]
WO WO9803218A1 · 1998 [cited by applicant]
WO WO0025848A2 · 2000 [cited by applicant]
WO WO0032238 · 2000 [cited by applicant]
WO WO2011147407A2 · 2001 [cited by applicant]
WO 2006130194 · 2006 [cited by applicant]
WO WO2009051614A1 · 2009 [cited by applicant]
WO WO2011008393A2 · 2011 [cited by applicant]
WO WO2011119159A1 · 2011 [cited by applicant]
WO WO2012122023A2 · 2012 [cited by applicant]
WO WO2013015941A1 · 2013 [cited by applicant]
WO 2013086698 · 2013 [cited by applicant]
WO 2013110158 · 2013 [cited by applicant]
WO WO2014066085A1 · 2014 [cited by applicant]
WO WO2014087395A1 · 2014 [cited by applicant]
WO WO2014177678A1 · 2014 [cited by applicant]
WO WO2015136106A1 · 2015 [cited by applicant]
WO WO2016073294A1 · 2016 [cited by applicant]
WO WO2016118923A1 · 2016 [cited by applicant]
WO WO2016172343A1 · 2016 [cited by applicant]
WO WO2018204782A1 · 2018 [cited by applicant]
WO WO2020172560A1 · 2020 [cited by applicant]
Vaughan, W.C., Review of balloon sinuplasty, Curr. Opin. Otolarngol Head Neck Surg., 16 (2008) pp. 2-9. (Year: 2008). [cited by examiner]
Jun. 19, 2020 declaration for U.S. Appl. No. 16/519,677. (Year: 2020). [cited by examiner]
“37 C.F.R. section 1.132 Declaration for U.S. Appl. No. 16/135,436, filed Jan. 13, 2020”, (2020), 5 pgs. [cited by applicant]
“Acetic Acid”, ChemSpider, Accessed online on Mar. 13, 2021 at <https://www.chemspider.com/Search.aspx?q=acetic+acidl>, (2021), 2 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Advisory Action mailed Jul. 18, 2018”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Corrected Notice of Allowability mailed May 5, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Examiner Interview Summary mailed Feb. 12, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed Apr. 2, 2018”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed May 3, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed Aug. 9, 2019”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Jan. 7, 2020”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Jan. 28, 2019”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Sep. 29, 2017”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Oct. 6, 2016”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Notice of Allowance mailed Apr. 22, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Feb. 7, 2020 to Non Final Office Action mailed Jan. 7, 2020”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Apr. 16, 2019 to Non Final Office Action mailed Jan. 28, 2019”, 29 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Jun. 1, 2018 to Final Office Action mailed Apr. 2, 2018”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Jul. 27, 2017 to Final Office Action mailed May 3, 2017”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Aug. 1, 2018 to Advisory Action mailed Jul. 18, 2018 and Final Office Action mailed Apr. 2, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Aug. 24, 2016 to Restriction Requirement mailed Jul. 12, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 3, 2019 to Final Office Action mailed Aug. 9, 2019”, 32 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 15, 2017 to Non Final Office Action mailed Sep. 29, 2017”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 28, 2016 to Non Final Office Action mailed Oct. 6, 2016”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Restriction Requirement mailed Jul. 12, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Corrected Notice of Allowability mailed Nov. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Final Office Action mailed May 15, 2020”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Non Final Office Action mailed Nov. 18, 2019”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Notice of Allowance mailed Sep. 30, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Notice of Non-Responsive Amendment mailed Jul. 1, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Feb. 10, 2020 to Non Final Office Action mailed Nov. 18, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Mar. 20, 2019 to Restriction Requirement mailed Feb. 8, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Jul. 9, 2019 to Non-Responsive Amendment mailed Jul. 1, 2019 & Restriction Requirement mailed Feb. 8, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Jul. 14, 2020 to Final Office Action mailed May 15, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Restriction Requirement mailed Feb. 8, 2019”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Corrected Notice of Allowability mailed Sep. 11, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Examiner Interview Summary mailed Apr. 8, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Final Office Action mailed Nov. 29, 2019”, 41 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Non Final Office Action mailed Mar. 5, 2020”, 48 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Non Final Office Action mailed Jul. 29, 2019”, 38 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Notice of Allowance mailed Jul. 10, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Notice of Non-Responsive Amendment mailed Mar. 8, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Jan. 13, 2020 to Final Office Action mailed Nov. 29, 2019”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Mar. 28, 2019 to Notice of Non-Responsive Amendment mailed Mar. 8, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Apr. 6, 2020 to Non Final Office Action mailed Mar. 5, 2020”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Aug. 21, 2019 to Non Final Office Action mailed Jul. 29, 2019”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Nov. 14, 2018 to Restriction Requirement mailed Nov. 2, 2018”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Restriction Requirement mailed Nov. 2, 2018”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Corrected Notice of Allowability mailed Nov. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Examiner Interview Summary mailed May 19, 2020”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Final Office Action mailed Aug. 21, 2020”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Final Office Action mailed Nov. 29, 2019”, 43 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Non Final Office Action mailed Mar. 19, 2020”, 56 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Non Final Office Action mailed Jul. 30, 2019”, 40 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Notice of Allowance mailed Oct. 7, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Notice of Non Responsive Amendment mailed Mar. 8, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Jan. 13, 2020 to Final Office Action mailed Nov. 29, 2019”, 27 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Mar. 28, 2019 to Notice of Non Responsive Amendment mailed Mar. 8, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed May 15, 2020 to Non Final Office Action mailed Mar. 19, 2020”, 29 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Sep. 4, 2020 to Final Office Action mailed Aug. 21, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Nov. 14, 2018 to Restriction Requirement mailed Nov. 2, 2018”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Aug. 21, 2019 to Non Final Office Action mailed Jul. 30, 2019”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Restriction Requirement mailed Nov. 2, 2018”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Corrected Notice of Allowability mailed May 13, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Final Office Action mailed Mar. 30, 2020”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Final Office Action mailed Jun. 14, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Non Final Office Action mailed Mar. 22, 2019”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Non Final Office Action mailed Nov. 18, 2019”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Notice of Allowance mailed Apr. 22, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Feb. 13, 2020 to Non Final Office Action mailed Nov. 18, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Mar. 31, 2020 to Final Office Action mailed Mar. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response Filed Apr. 24, 2019 to Non-Final Office Action Mailed Mar. 22, 2019”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Sep. 11, 2019 to Final Office Action mailed Jun. 14, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Corrected Notice of Allowability mailed Nov. 30, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Non Final Office Action mailed Mar. 19, 2020”, 31 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Notice of Allowance mailed Sep. 21, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Response filed Jun. 19, 2020 to Non Final Office Action mailed Mar. 19, 2020”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Response filed Dec. 13, 2019 to Restriction Requirement mailed Nov. 20, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Restriction Requirement mailed Nov. 20, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Final Office Action mailed Aug. 21, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Non Final Office Action mailed Feb. 6, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Notice of Allowance mailed Oct. 21, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed May 6, 2020 to Non Final Office Action mailed Feb. 6, 2020”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed Sep. 4, 2020 to Final Office Action mailed Aug. 21, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed Oct. 31, 2019 to Restriction Requirement mailed Oct. 18, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Restriction Requirement mailed Oct. 18, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Examiner Interview Summary mailed Jul. 12, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Final Office Action mailed May 25, 2021”, 44 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Non Final Office Action mailed Mar. 18, 2021”, 32 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Response filed Apr. 6, 2021 to Non Final Office Action mailed Mar. 18, 2021”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Response filed Dec. 10, 2020 to Restriction Requirement mailed Nov. 17, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Restriction Requirement mailed Nov. 17, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Corrected Notice of Allowability mailed Mar. 17, 2021”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Non Final Office Action mailed Oct. 29, 2020”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Notice of Allowance mailed Jan. 4, 2021”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Response filed Dec. 4, 2020 to Non Final Office Action mailed Oct. 29, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Corrected Notice of Allowability mailed Jul. 12, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Non Final Office Action mailed Mar. 3, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Notice of Allowance mailed Jun. 14, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Response filed May 27, 2022 to Non Final Office Action mailed Mar. 3, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,114, Non Final Office Action mailed Mar. 3, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,114, Notice of Allowance mailed Jun. 14, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,114, Response filed May 27, 2022 to Non Final Office Action mailed Mar. 3, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,140, Non Final Office Action mailed Feb. 19, 2021”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,140, Notice of Allowance mailed Mar. 18, 2021”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,140, Notice of Allowance/Base Issue Fee mailed Mar. 18, 2021”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,140, Response filed Mar. 9, 2021 to Non Final Office Action mailed Feb. 19, 2021”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,199, Non Final Office Action mailed Feb. 19, 2021”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,199, Notice of Allowance mailed Mar. 19, 2021”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,199, Response filed Mar. 9, 2021 to Non Final Office Action mailed Feb. 19, 2021”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/107,136, Corrected Notice of Allowability mailed Jul. 12, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/107,136, Non Final Office Action mailed Mar. 4, 2022”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/107,136, Notice of Allowance mailed Jun. 23, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 17/107,136, Response filed May 27, 2022 to Non Final Office Action mailed Mar. 4, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/108,517, Corrected Notice of Allowability mailed Jul. 12, 2022”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/108,517, Non Final Office Action mailed Mar. 3, 2022”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/108,517, Notice of Allowance mailed Jun. 14, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/108,517, Response filed May 27, 2022 to Non Final Office Action mailed Mar. 3, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/133,088, Corrected Notice of Allowability mailed Aug. 24, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/133,088, Notice of Allowance mailed Jul. 25, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/133,088, Preliminary Amendment filed Dec. 2, 2021”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/133,088, Preliminary Amendment filed Dec. 29, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/208,518, Corrected Notice of Allowability mailed Feb. 15, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/208,518, Non Final Office Action mailed Oct. 6, 2022”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/208,518, Notice of Allowance mailed Jan. 30, 2023”, 10 pgs. [cited by applicant]